About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Lung Cancer Genomic Testing Market Size, CAGR of 8%, Share, Report to 2032
Lung Cancer Genomic Testing Market

Lung Cancer Genomic Testing Market Size, Share & Trends Analysis Report By Type (Products, Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence in Situ Hybridization), By Sample Type (Tissue biopsy, Liquid biopsy), By Panel Type (Multi-Gene panels, Single-Gene panels), By End-User (Research organizations, Hospitals/Clinics, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI2129DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Lung Cancer Genomic Testing Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    7. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Products
          1. By Value
        3. Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
        4. Fluorescence in Situ Hybridization
          1. By Value
      3. By Sample Type
        1. Introduction
          1. Sample Type By Value
        2. Tissue biopsy
          1. By Value
        3. Liquid biopsy
          1. By Value
      4. By Panel Type
        1. Introduction
          1. Panel Type By Value
        2. Multi-Gene panels
          1. By Value
        3. Single-Gene panels
          1. By Value
      5. By End-User
        1. Introduction
          1. End-User By Value
        2. Research organizations
          1. By Value
        3. Hospitals/Clinics
          1. By Value
        4. Diagnostic Laboratories
          1. By Value
    8. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    7. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Products
          1. By Value
        3. Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
        4. Fluorescence in Situ Hybridization
          1. By Value
      3. By Sample Type
        1. Introduction
          1. Sample Type By Value
        2. Tissue biopsy
          1. By Value
        3. Liquid biopsy
          1. By Value
      4. By Panel Type
        1. Introduction
          1. Panel Type By Value
        2. Multi-Gene panels
          1. By Value
        3. Single-Gene panels
          1. By Value
      5. By End-User
        1. Introduction
          1. End-User By Value
        2. Research organizations
          1. By Value
        3. Hospitals/Clinics
          1. By Value
        4. Diagnostic Laboratories
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    7. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Products
          1. By Value
        3. Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
        4. Fluorescence in Situ Hybridization
          1. By Value
      3. By Sample Type
        1. Introduction
          1. Sample Type By Value
        2. Tissue biopsy
          1. By Value
        3. Liquid biopsy
          1. By Value
      4. By Panel Type
        1. Introduction
          1. Panel Type By Value
        2. Multi-Gene panels
          1. By Value
        3. Single-Gene panels
          1. By Value
      5. By End-User
        1. Introduction
          1. End-User By Value
        2. Research organizations
          1. By Value
        3. Hospitals/Clinics
          1. By Value
        4. Diagnostic Laboratories
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Singapore
    13. Taiwan
    14. South East Asia
    15. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    7. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Products
          1. By Value
        3. Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
        4. Fluorescence in Situ Hybridization
          1. By Value
      3. By Sample Type
        1. Introduction
          1. Sample Type By Value
        2. Tissue biopsy
          1. By Value
        3. Liquid biopsy
          1. By Value
      4. By Panel Type
        1. Introduction
          1. Panel Type By Value
        2. Multi-Gene panels
          1. By Value
        3. Single-Gene panels
          1. By Value
      5. By End-User
        1. Introduction
          1. End-User By Value
        2. Research organizations
          1. By Value
        3. Hospitals/Clinics
          1. By Value
        4. Diagnostic Laboratories
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Products
        1. By Value
      3. Services
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Polymerase Chain Reaction (PCR)
        1. By Value
      3. Next-Generation Sequencing (NGS)
        1. By Value
      4. Fluorescence in Situ Hybridization
        1. By Value
    4. By Sample Type
      1. Introduction
        1. Sample Type By Value
      2. Tissue biopsy
        1. By Value
      3. Liquid biopsy
        1. By Value
    5. By Panel Type
      1. Introduction
        1. Panel Type By Value
      2. Multi-Gene panels
        1. By Value
      3. Single-Gene panels
        1. By Value
    6. By End-User
      1. Introduction
        1. End-User By Value
      2. Research organizations
        1. By Value
      3. Hospitals/Clinics
        1. By Value
      4. Diagnostic Laboratories
        1. By Value
    7. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Products
          1. By Value
        3. Services
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Polymerase Chain Reaction (PCR)
          1. By Value
        3. Next-Generation Sequencing (NGS)
          1. By Value
        4. Fluorescence in Situ Hybridization
          1. By Value
      3. By Sample Type
        1. Introduction
          1. Sample Type By Value
        2. Tissue biopsy
          1. By Value
        3. Liquid biopsy
          1. By Value
      4. By Panel Type
        1. Introduction
          1. Panel Type By Value
        2. Multi-Gene panels
          1. By Value
        3. Single-Gene panels
          1. By Value
      5. By End-User
        1. Introduction
          1. End-User By Value
        2. Research organizations
          1. By Value
        3. Hospitals/Clinics
          1. By Value
        4. Diagnostic Laboratories
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Lung Cancer Genomic Testing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. QIAGEN N.V.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Agilent Technologies, Inc.
    3. Thermo Fisher Scientific, Inc.
    4. Quest Diagnostics Incorporated
    5. Laboratory Corporation of America Holdings
    6. CENTOGENE N.V.
    7. BGI
    8. CeGaT GmbH
    9. Illumina, Inc.
    10. Hoffmann-La Roche Ltd.
    11. Abbott Laboratories
    12. CD Genomics
    13. NeoGenomics Laboratories
    14. Admera Health
    15. OncoDNA
    16. OPKO Health, Inc.
    17. Invitae Corporation
    18. Veracyte, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Cancer Genetic Testing Market Size The global cancer genetic testing market size was valued at USD 6.70 billion in 2024 and is projected to reach from USD 7.47 billion in 2025 to USD 17.98 billion by 2033, growing at a CAGR of 11.6% during the forec
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.